GS
ABCL icon

GTS Securities’s AbCellera Biologics ABCL Stock Holding History

GTS Securities’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,479
Closed -$55.8K – 1234
2024
Q3 		$55.8K Buy
21,479
+3,124
+17% +$8.66K ﹤0.01% 3879
2024
Q2 		$54.3K Sell
18,355
-9,085
-33% -$34.4K ﹤0.01% 3699
2024
Q1 		$124K Sell
27,440
-4,308
-14% -$22K ﹤0.01% 3478
2023
Q4 		$181K Buy
31,748
+15,605
+97% +$72.3K ﹤0.01% 3605
2023
Q3 		$74.3K Buy
+16,143
New +$98.2K ﹤0.01% 3650

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GTS Securities's ABCL Position: Q4 2024 in Review

GTS Securities sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 21,479 shares — an estimated $55.8K sold.

GTS Securities first reported a position in ABCL in Q3 2023 and held it in 5 quarters. The position peaked at $181K in Q4 2023. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • GTS Securities reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 21,479 AbCellera Biologics shares in Q4 2024, an estimated $55.8K.
  • GTS Securities first reported a position in AbCellera Biologics in Q3 2023 and held it in 5 quarters.
  • GTS Securities's AbCellera Biologics position peaked at $181K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.